ClinicalTrials.gg
RecruitingNCT07168850FUTUREUpdated Nov 5, 2026

Focused Ultrasound Unilateral Pallidotomy for Medication-Refractory Limb Dystonia

An interventional study of Exablate MR-guided Focused Ultrasound Pallidotomy and Sham Sham Exablate MRgFUS Pallidotomy in Limb Dystonia, Idiopathic Dystonia and Medication-refractory Dystonia, sponsored by Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta. Recruiting at 4 sites in Italy. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Jan 2025, registered Aug 2025).
  • Started Jan 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 11 studies in Dystonia with a site in Italy — 5 open to participants now, 6 under way, none of them phase 3. Dystonia · Italy.

Started
2025
the only one that year
No phase
2 of 11
1 open now
Registered
11th of 11
by date
Lead sponsor
2 of 11
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta

Among the 11 studies in Dystonia with a site in Italy, this one is the only one that started in 2025, is one of 2 with no phase, and was the 11th registered.

Dystonia

213 studies on the registry are indexed under Dystonia; 54 are open to participants now.

Browse Dystonia studies →

Open to participants now

5 of the 11 studies in Dystonia with a site in Italy are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 41 Dystonia studies recruiting now, 19 (46%) set no upper age limit and 10 (24%) stop at 75 or younger; 18 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Dystonia with a site in Italy, or all of them as a file.
02

Study summary

The goal of this clinical trial is to find out if a non-invasive procedure called focused ultrasound can safely and effectively treat limb dystonia in adults who have not improved with medications or botulinum toxin injections.

The main questions it aims to answer are:

  • Does focused ultrasound reduce the severity of limb dystonia symptoms?
  • Is the procedure safe and well tolerated?

Researchers will compare people who receive focused ultrasound treatment to those who receive a sham procedure (a look-alike procedure without active treatment) to see if the treatment works.

Focused ultrasound works by producing a very small (millimeter-size) lesion in a deep brain region. In this study, the lesion is located in a region called globus pallidus, which helps control movement.

Participants will:

  • Be randomly assigned to one of two groups: focused ultrasound or sham
  • Undergo a procedure using MRI and focused ultrasound to target a part of the brain called the globus pallidus
  • Be followed for 6 months after treatment to assess changes in symptoms, quality of life, and brain function
  • Participants in the sham group will be offered the real treatment after 3 months

This study may offer a new non-surgical treatment option for people with dystonia affecting the arm or leg, whose pharmacological control is unsatisfactory.

Read the detailed description

The FUTURE study is a prospective, randomized, double-blind, sham-controlled, multicenter national clinical trial aimed at assessing the efficacy and safety of unilateral MR-guided focused ultrasound (MRgFUS) pallidotomy in patients with limb dystonia that is refractory to standard pharmacological treatments.

Dystonia is a movement disorder characterized by sustained or intermittent muscle contractions, causing abnormal movements or postures. In many cases, focal or segmental dystonias affecting the limbs can be managed with oral medications and botulinum toxin (BoNT) injections. However, a subset of patients does not respond adequately to these treatments. For such individuals, surgical intervention may offer relief, yet it remains underutilized due to concerns about invasiveness and complications.

Recent advancements in non-invasive neurosurgical techniques have introduced MRgFUS pallidotomy, a procedure that uses focused ultrasound beams under real-time MRI guidance to precisely ablate small brain targets-in this case, the globus pallidus internus (GPi). The FUTURE study specifically explores this technique as a less invasive alternative to deep brain stimulation, especially for patients with focal or segmental limb dystonia who are ineligible or reluctant to undergo conventional surgery.

The trial will enroll 34 adult patients with idiopathic or genetic limb dystonia that has proven resistant to pharmacologic and BoNT treatment. These patients will be randomly assigned in a 1:1 ratio to either:

  • an active treatment group, undergoing unilateral GPi lesioning via MRgFUS,
  • or a sham control group, receiving the same procedural setup but without therapeutic sonications.

At three months post-randomization, all patients in the sham group will cross over to receive the active MRgFUS treatment, allowing within-subject comparisons while ensuring ethical access to the therapeutic intervention. The follow-up period for each patient will last six months after active treatment, totaling a maximum of nine months of participation.

The primary endpoint is the change in motor severity as measured by the Burke-Fahn-Marsden Dystonia Rating Scale (BFMDRS) at three months post-treatment. Secondary endpoints include adverse event frequency, patient and clinician global impressions of change, disability assessments (e.g., QuickDASH), quality of life (SF-36), and neurocognitive testing.

Additionally, the study will incorporate neurophysiological (TMS) and neuroimaging (resting-state fMRI) techniques to investigate treatment-induced changes in cortical excitability, plasticity, and functional connectivity, providing insight into the neural mechanisms underlying clinical improvement.

The FUTURE study is coordinated by the Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy with participation from other three major Italian neurological institutes. It represents a pioneering effort to evaluate focused ultrasound as a non-invasive therapeutic option for patients with disabling and treatment-resistant forms of limb dystonia.

03

Conditions studied

  • Limb Dystonia
  • Idiopathic Dystonia
  • Medication-refractory Dystonia
  • Dystonia, Focal

Keywords

  • Focused Ultrasound
  • MRgFUS
  • Pallidotomy
  • Dystonia
  • Exablate
  • Neuromodulation
  • fMRI
  • TMS
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-80 years
  • Able and willing to consent and attend visits
  • Idiopathic or hereditary limb dystonia (focal, segmental, or multifocal; isolated or combined)
  • to oral therapy and botulinum toxin
  • Stable medication for ≥30 days and ≥90 days since last BoNT
  • Capable of communicating during Exablate procedure

Exclusion criteria

Exclusion Criteria:

  • Acquired secondary dystonia
  • Dementia or other neurodegenerative disorders
  • Any or unstable medical condition, which, in the opinion of the principal investigator or the clinician delegated by the principal investigator, may put the participant at risk when participating in the study (e.g., unstable heart disease or coagulopathy; uncontrolled psychiatric comorbidity)
  • Prior deep brain stimulation or other brain surgery
  • Any to MRI
  • Skull Density Ratio (SDR) \< 0.40
  • Significant brain lesions (eg brain tumor, significant white matter lesions or globus pallidus interna lesions on baseline MRI)
  • Pregnancy
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
34 participants (estimated)

Study arms

  • Experimental
    Active Pallidotomy (MRgFUS)

    Patients undergo unilateral pallidotomy using Exablate system under MRI guidance.

    Device: Exablate MR-guided Focused Ultrasound Pallidotomy

  • Sham comparator
    Sham Procedure

    Identical setup without thermal lesioning. Participants cross over to active Pallidotomy after 3 months.

    Device: Exablate MR-guided Focused Ultrasound Pallidotomy · Device: Sham Sham Exablate MRgFUS Pallidotomy

Interventions

  • DeviceExablate MR-guided Focused Ultrasound Pallidotomy

    Active Pallidotomy

  • DeviceSham Sham Exablate MRgFUS Pallidotomy

    Sham procedure. Identical setup without thermal lesioning. Participants cross over to Active Pallidotomy after 3 months.

06

What researchers measure

Primary outcomes

  1. Chenge in the Burke-Fahn-Marsden Dystonia Rating Scale (BFMDRS)

    The BFMDRS has a maximum score of 120 for the movement subscale and 30 for the disability subscale. Higher scores indicating more severe dystonia.

    Time frame: Baseline to Week 12

Secondary outcomes

  1. Incidence of treatment-related adverse events

    Assessment of any treatment-related adverse events throughout the whole study period

    Time frame: Baseline to Week 24

  2. Changes in the Quick Disabilities of Arm, Shoulder & Hand (Quick-DASH) score

    The QuickDASH is a shortened, 11-item version of the DASH Outcome Measure, designed to assess physical function and symptom severity related to the arm, shoulder, and hand. Maximum score 100; the greater the score the grear the disability.

    Time frame: Baseline, Week 12 and Week 24

  3. Changes in the Clinical Global Impression of Change (CGIC) score

    The CGIC is a 7-point scale used to assess the degree of change in a patient's condition since the start of treatment or another defined baseline. Lower scores indicates improvement and higher scores indicating worsening of the patient's condition.

    Time frame: Baseline, week 12 and week 24

  4. Patient Global Impression of Change (PGIC)

    The maximum score of the PGIC is 7: the higher the score the higher the improvement reported by a patient.

    Time frame: Baseline, Week 12 and week 24

  5. Change in the 36-Item Short Form Survey (SF-36) score

    The SF-36 questionnaire has a maximum score of 100 for each of its eight scaled scores (physical functioning, role limitations due to physical health, bodily pain, general health, vitality, social functioning, role limitations due to emotional problems, and mental health). The higher the scores the more favorable is health state within that specific dimension.

    Time frame: Baseline, week 12 and week 24

  6. Changes in the Short-Interval Cortical Inhibition (SICI)

    This is a neurophysiological measure of inhibitory processes within the motor cortex, assessed using Transcranial Magnetic Stimulation, which is measured as the relative amplitude reduction of motor evoked potentials from the test stimulus when it is preceded by the conditioning stimulus. The greater the change in SICI, the greater the pallidotomy-induced changes in motor cortex intracortical inhibitory circuits

    Time frame: Baseline and Week 24

  7. Changes in intracortical facilitation (ICF)

    This is a neurophysiological measures of cortical excitability, assessed using paired-pulse Transcranial Magnetic Stimulation, which describes an increase in the magnitude of a motor evoked potential in a target muscle when a suprathreshold test pulse is preceded by a subthreshold conditioning pulse at specific interstimulus intervals. The greater the change in ICF, the greater the pallidotomy-induced changes in intracortical excitatory circuits

    Time frame: Baseline and Week 24

  8. Changes in Paired Associative Stimulation (PAS)

    This is a neurophysiological measure of cortical plasticity assessed using transcranial magnetic stimulation. The greater the change in PAS, the greater the pallidotomy-induced changes in motor cortex synaptic plasticity

    Time frame: Baseline and week 24

  9. Changes in brain activity (using functional connectivity) using resting-state functional magnetic resonance imaging (rs-fMRI)

    The investigators will conduct a region-of-interest analysis to calculate changes of fMRI functional connectivity between baseline and post-pallidotomy.

    Time frame: Baseline and Week 24

  10. Changes in pallidotomy lesion morphology via contrast MRI

    To evaluate the morphological changes of the lesion after 24 hours, 3 months and 6 months from pallidotomy using contrast-enhanced brain MRI and their relationship with clinical changes including adverse events.

    Time frame: 24-hour after the procedure, week 12 and week 24

  11. Changes in the Montreal Cognitive Assessment (MoCA) score

    Changes in the Montreal Cognitive Assessment (MoCA) score, a 30-point test of global cognitive functions. Score range: 0-30, with lower scores indicating worse cognitive function and higher scores indicating better cognitive function.

    Time frame: Baseline, week 12 and week 24

  12. Change in Digit Span test score

    Change in Digit Span test score, a cognitive test assessing memory functions. Score range: 0-\[insert maximum score for the test\], with lower scores indicating greater memory impairment and higher scores indicating better memory function.

    Time frame: Baseline, week 12 and week 24]

  13. Change in the Stroop Test score

    Change in Stroop Test scores, a neuropsychological test assessing frontal-lobe executive cognitive function. Score range: \[insert minimum\]-\[insert maximum\], with higher scores or slower reaction times indicating worse executive cognitive function.

    Time frame: Baseline, week 12 and week 24

07

Study locations

4 of 4 sites recruiting
08

References and documents

Publications

  • Rothwell JC, Hallett M, Berardelli A, Eisen A, Rossini P, Paulus W. Magnetic stimulation: motor evoked potentials. The International Federation of Clinical Neurophysiology. Electroencephalogr Clin Neurophysiol Suppl. 1999;52:97-103. No abstract available. PubMed 10590980 ↗
  • Sohn YH, Hallett M. Disturbed surround inhibition in focal hand dystonia. Ann Neurol. 2004 Oct;56(4):595-9. doi: 10.1002/ana.20270. PubMed 15455393 ↗
  • Burke RE, Fahn S, Marsden CD, Bressman SB, Moskowitz C, Friedman J. Validity and reliability of a rating scale for the primary torsion dystonias. Neurology. 1985 Jan;35(1):73-7. doi: 10.1212/wnl.35.1.73. PubMed 3966004 ↗
  • Horisawa S, Yamaguchi T, Abe K, Hori H, Fukui A, Iijima M, Sumi M, Hodotsuka K, Konishi Y, Kawamata T, Taira T. Magnetic Resonance-Guided Focused Ultrasound Thalamotomy for Focal Hand Dystonia: A Pilot Study. Mov Disord. 2021 Aug;36(8):1955-1959. doi: 10.1002/mds.28613. Epub 2021 May 29. PubMed 34050695 ↗
  • Stieglitz LH, Mahendran S, Oertel MF, Baumann CR. Bilateral Focused Ultrasound Pallidotomy for Parkinson-Related Facial Dyskinesia-A Case Report. Mov Disord Clin Pract. 2022 May 9;9(5):647-651. doi: 10.1002/mdc3.13462. eCollection 2022 Jul. PubMed 35844284 ↗
  • Krishna V, Fishman PS, Eisenberg HM, Kaplitt M, Baltuch G, Chang JW, Chang WC, Martinez Fernandez R, Del Alamo M, Halpern CH, Ghanouni P, Eleopra R, Cosgrove R, Guridi J, Gwinn R, Khemani P, Lozano AM, McDannold N, Fasano A, Constantinescu M, Schlesinger I, Dalvi A, Elias WJ. Trial of Globus Pallidus Focused Ultrasound Ablation in Parkinson's Disease. N Engl J Med. 2023 Feb 23;388(8):683-693. doi: 10.1056/NEJMoa2202721. PubMed 36812432 ↗
  • Hariz M. Pros and Cons of Ablation for Functional Neurosurgery in the Neurostimulation Age. Neurosurg Clin N Am. 2023 Apr;34(2):291-299. doi: 10.1016/j.nec.2022.11.006. Epub 2023 Jan 30. PubMed 36906335 ↗
  • Horisawa S, Fukui A, Takeda N, Kawamata T, Taira T. Safety and efficacy of unilateral and bilateral pallidotomy for primary dystonia. Ann Clin Transl Neurol. 2021 Apr;8(4):857-865. doi: 10.1002/acn3.51333. Epub 2021 Mar 15. PubMed 33720521 ↗
  • Centen LM, Oterdoom DLM, Tijssen MAJ, Lesman-Leegte I, van Egmond ME, van Dijk JMC. Bilateral Pallidotomy for Dystonia: A Systematic Review. Mov Disord. 2021 Mar;36(3):547-557. doi: 10.1002/mds.28384. Epub 2020 Nov 20. PubMed 33215750 ↗
  • Jankovic J. Medical treatment of dystonia. Mov Disord. 2013 Jun 15;28(7):1001-12. doi: 10.1002/mds.25552. PubMed 23893456 ↗
  • Hallett M, Benecke R, Blitzer A, Comella CL. Treatment of focal dystonias with botulinum neurotoxin. Toxicon. 2009 Oct;54(5):628-33. doi: 10.1016/j.toxicon.2008.12.008. Epub 2008 Dec 13. PubMed 19103214 ↗

Individual participant data

Plan to share: Yes — Data will be shared upon reasonable request with appropriate safeguards for privacy and confidentiality

Time frame: Data requests can be submitted starting 9 months after article publication and the data will be made accessible for up to 24 months. Extensions will be considered on a case-by-case basis

Access criteria: Access to trial individual participant data can be requested by qualified researchers engaging in independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan and execution of a Data Sharing Agreement. For more information or to submit a request, please contact the P.I. of the study

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Feb 2027, 25 months after the start.

Of 48 non-industry interventional studies with no phase under Dystonia, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 75. This study's planned 25 months is below that.

Counting every sponsor, half of 49 studies reached it within 50 months; a quarter within 26 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 20, 2025
First posted
Sep 11, 2025
StartActual
Jan 27, 2025
Primary completionEst.
Feb 28, 2027
CompletionEst.
Feb 28, 2027
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07168850
Lead sponsor
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Collaborators
Azienda ULSS 3 Serenissima, IRCCS Centro Neurolesi Bonino Pulejo, Azienda Ospedaliera Villa Sofia
Responsible party
Sponsor
First posted
Sep 11, 2025
Start date
Jan 27, 2025
Primary completion
Feb 28, 2027 (estimated)
Completion
Feb 28, 2027 (estimated)
Last update
Nov 5, 2026

Study contacts

Roberto Eleopra
Contact
roberto.eleopra@istituto-besta.it
+390223942552
Giovanna Zorzi
Contact
giovanna.zorzi@istituto-besta.it
+390223942712

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion